Keyphrases
Phase I Study
100%
Multiple Myeloma
100%
Bortezomib
100%
Granulocyte Colony-stimulating Factor (G-CSF)
100%
Stem Cell Mobilization
100%
Mobilization Effect
25%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Peripheral Blood
16%
Myeloma Cells
16%
Microliter
16%
Randomized Trial
8%
Purging
8%
Dose-limiting Toxicity
8%
Dose Level
8%
Engraftment
8%
CD34+ Cells
8%
Apheresis
8%
Institutional Guidelines
8%
Graft Viability
8%
Medicine and Dentistry
Multiple Myeloma
100%
Stem Cell Mobilization
100%
Granulocyte Colony Stimulating Factor
100%
Bortezomib
100%
Autologous Stem Cell Transplantation
16%
Myeloma Cell
16%
Single Drug Dose
8%
Apheresis
8%
Engraftment
8%
Immunology and Microbiology
Stem Cell
100%
Multiple Myeloma
100%
Granulocyte Colony-Stimulating Factor
100%
Myeloma Cell
22%
Autologous Stem Cell Transplantation
22%
Engraftment
11%
CD34
11%
Apheresis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Multiple Myeloma
100%
Granulocyte Colony Stimulating Factor
100%
Myeloma
8%
Material Science
Stem Cell
100%
Colony Stimulating Factor
100%